Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

PROCEPT BioRobotics Corporation - Common Stock (NQ:PRCT)

39.56 -1.67 (-4.05%)
Streaming Delayed Price Updated: 3:43 PM EDT, Aug 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about PROCEPT BioRobotics Corporation - Common Stock

< Previous 1 2 3 4 5 6 Next >
PROCEPT BioRobotics to Present at Upcoming 2024 Truist Securities MedTech Conference on June 18, 2024
From PROCEPT BioRobotics
Via GlobeNewswire
From Science Fiction to Reality: 3 Robotics Stocks for Automatic Riches
Artificial intelligence companies have already soared over the past year. These robotics stocks could be the next big thing. 
Via InvestorPlace
Topics Artificial Intelligence
PROCEPT BioRobotics to Present at Upcoming 2024 Leerink Partners Healthcare Crossroads Conference and 44th Annual William Blair Growth Stock Conference
From PROCEPT BioRobotics
Via GlobeNewswire
Unveiling 4 Analyst Insights On PROCEPT BioRobotics
 
Via Benzinga
PROCEPT BioRobotics: Q4 Earnings Insights
 
Via Benzinga
Earnings Scheduled For February 27, 2024
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million. 
Via Benzinga
PROCEPT BioRobotics's Earnings: A Preview
 
Via Benzinga
Real-World, Long-Term Data Demonstrate Sustained Benefits of Aquablation Therapy for Men with Benign Prostatic Hyperplasia
Data from the Icahn School of Medicine at Mount Sinai and Potomac Urology presented at the 2024 AUA Annual Meeting highlight Aquablation therapy’s potential to become the new standard of care in BPH... 
From PROCEPT BioRobotics
Via GlobeNewswire
Intuitive Surgical Builds On Its Robotic Surgery Prowess. But Challengers Are Coming.
As new robotic surgery systems loom, Intuitive Surgical investors await a "game-changer." 
Via Investor's Business Daily
PRCT Stock Earnings: PROCEPT BioRobotics Beats EPS, Beats Revenue for Q1 2024
PRCT stock results show that PROCEPT BioRobotics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
PROCEPT BioRobotics Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
From PROCEPT BioRobotics
Via GlobeNewswire
Demystifying PROCEPT BioRobotics: Insights From 4 Analyst Reviews
 
Via Benzinga
Late Breaking Abstract Presented at the Japanese Urological Association Annual Meeting on Aquablation Therapy Outcomes for Men in Japan with Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia
Japanese post market survey supports safety and efficacy of Aquablation therapy 
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics Announces 12 Scientific Research Presentations on Aquablation Therapy for the Treatment of Benign Prostatic Hyperplasia at the 2024 AUA Annual Meeting
Presentations include first published experience report of same-day discharge in an ambulatory surgical center, real-world data outcomes and 5-year data comparison between two FDA trials 
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics Corp. Announces Investor Event at 2024 AUA Annual Meeting in San Antonio, Texas
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics to Report First Quarter 2024 Financial Results on May 1, 2024 and Attend the 2024 Bank of America Healthcare Conference on May 15, 2024
From PROCEPT BioRobotics
Via GlobeNewswire
Truist Securities Maintains Buy Rating for PROCEPT BioRobotics: Here's What You Need To Know
 
Via Benzinga
PROCEPT BioRobotics Reports Fourth Quarter and Full Year 2023 Results
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics to Present at the 44th Annual TD Cowen Health Care Conference in Boston
From PROCEPT BioRobotics
Via GlobeNewswire
Procept BioRobotics Shares Are Higher Today, CEO Touts 'Strong Surgeon Interest'
Procept BioRobotics Corp (NASDAQ: PRCT) shares are trading higher after the company announced fourth-quarter (Q4) FY23  
Via Benzinga
PROCEPT BioRobotics® Announces Preliminary Fourth Quarter Revenue of $43.3 million to $43.6 million
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics Stock Scores Rising Relative Strength
The Relative Strength (RS) Rating for PROCEPT BioRobotics stock headed into a new percentile Tuesday, as it got a lift from 70 to 77. 
Via Investor's Business Daily
PROCEPT BioRobotics to Present at the 35ᵗʰ Annual Piper Sandler Healthcare Conference in New York City
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics® Reports Third Quarter 2023 Financial Results and Increases 2023 Revenue Guidance
From PROCEPT BioRobotics
Via GlobeNewswire
The 7 Best Tech Stocks To Buy Now: October 2023
Although the innovation sector got overheated, certain underappreciated ideas make up the best tech stocks to buy now. 
Via InvestorPlace
PROCEPT BioRobotics to Report Third Quarter 2023 Financial Results on November 1, 2023
From PROCEPT BioRobotics
Via GlobeNewswire
The National Institute for Health and Care Excellence Endorses Aquablation® Therapy with "Standard Arrangements" Recommendation
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics Announces New Corporate Headquarters in San Jose
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics® Receives U.S. FDA Investigational Device Exemption to Investigate Aquablation® Therapy for Prostate Cancer
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics® Announces First Commercial Aquablation Therapy Procedures in Japan
From PROCEPT BioRobotics
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.